ABBV · Earnings call · 2026Q3T · Full report

Tavapadon Launch Demand

AbbVie Inc. · 2026-10-30 · Importance 34 · Surprise 42

Management reported strongly positive initial market feedback for tavapadon, launched only a few weeks earlier, and said demand in the funnel exceeded initial expectations. Physicians responded to trial results showing levodopa/carbidopa dose escalation could be frozen for about 85 weeks, alongside low reported somnolence and few to no observed impulse-control disorders. Patients are also asking neurologists and movement-disorder specialists about the treatment. Access remains limited to enrollments and medical-exception processes, and AbbVie noted it had missed the Medicare access window for 2027.

Key facts

• AbbVie said early Parkinson’s patients taking tavapadon very rarely need to start levodopa/carbidopa for around 85 weeks.
• In patients already taking levodopa/carbidopa, AbbVie said tavapadon can effectively freeze the dose for approximately 1.5 years.
• AbbVie said tavapadon allows patients optimizing oral therapy to do so quickly, with efficacy observed early.
• AbbVie reported positive initial market feedback for tavapadon, while noting that the launch had been underway for only a few weeks.
• AbbVie said adding tavapadon essentially froze dose escalations in almost all patients for 85 weeks and counting.
• AbbVie said tavapadon demand in the funnel exceeded initial expectations.
• AbbVie said tavapadon showed low rates of somnolence and very few to no observed impulse control disorders in trials.